


See "Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study" on page 223.



Supplementary Fig. 4. Comparison of antibodies to infliximab (ATI) levels by assay B in the loss of response (LOR) and remission groups. Assay B was used to measure ATI levels in both the LOR and remission groups ($P=0.0014$).